-
Regular withdrawal of drugs on the Internet has become the norm, and another batch of drugs has been withdrawn from the Internet
Time of Update: 2022-03-06
In fact, since last year, Shanghai has issued a number of online purchase notices, and 18 drugs have been closed for purchase because medical institutions have not completed the negotiation and acceptance .
-
210 drug reviews!
Time of Update: 2022-03-06
According to the notice, 210 products were reviewed and purchased online, of which 122 pharmaceutical companies including Amoxicillin Capsules of Yuekang Pharmaceutical Group, Omeprazole Enteric-Coated Tablets of Fangsheng Pharmaceutical, Bicalutamide Tablets of Jianghaizheng Pharmaceutical, Linezolid Glucose Injection of Chia Tai Tianqing Pharmaceutical Group 's products .
-
Vancomycin Hydrochloride for Injection by Puli Pharmaceuticals obtained the marketing authorization of the Ministry of Health of Costa Rica
Time of Update: 2022-03-06
It is indicated for penicillin-allergic patients, patients who cannot receive or respond to other drugs (including penicillin or cephalosporins), and infections caused by vancomycin-sensitive organisms that are resistant to other antimicrobials .
-
Since 2022, 28 pharmaceutical companies have launched buybacks
Time of Update: 2022-03-06
, and repurchase shares in a centralized bidding transaction, and the shares to be repurchased will be used to implement employee stock ownership plans or equity incentives .
-
Domestic pharmaceutical companies are attacking innovative drugs, but these problems remain to be solved
Time of Update: 2022-03-06
In addition to Pien Tze Huang, many pharmaceutical companies have been increasing investment in the research and development of innovative drugs in recent years.
-
In 2022, the field of medicine and biology will still be favored by research institutions
Time of Update: 2022-03-06
Specifically, according to the investor relations activity record sheet released by Mindray Medical on January 17, 2022, from January 4 to January 7, January 10 to January 14, and January 17, the company received a total of 742 participants from 430 institutions .
-
The Offensive and Defensive Way of Pharmaceutical Licensing Transactions
Time of Update: 2022-03-06
This requires the licensor and the licensee to clearly agree on their respective rights and obligations at all stages of research and development, production and commercialization in the pharmaceutical licensing agreement .
-
Novel drug development for endometriosis: GnRH antagonist competition and nonhormonal target exploration
Time of Update: 2022-03-06
By April ChenAt present, the main development direction of new EMs drugs is focused on GnRH antagonists that inhibit estrogen levels, such as AbbVie Elagolix, Pfizer Relugolix, etc.
-
In 2022, localities will continue to vigorously promote the inheritance, innovation and development of traditional Chinese medicine
Time of Update: 2022-03-06
For example, since December 2021, four national-level policies have been issued, including the "Guiding Opinions on Medical Insurance Supporting the Inheritance and Innovation of Traditional Chinese Medicine" .
-
Under favorable policies, the growth of innovative traditional Chinese medicine drugs can be expected
Time of Update: 2022-03-06
In order to encourage the innovation of traditional Chinese medicine, in recent years, policies on promoting the innovation of traditional Chinese medicine, examination and approval, development of formula granules, medical insurance and payment, and personnel training have been issued frequently .
-
Haisco's innovative drug HSK36212 capsule received the "Notice of Acceptance" for clinical trial application
Time of Update: 2022-03-06
Preclinical studies have shown that HSK36212 capsules can inhibit the expression of genes related to renal injury and fibrosis at the molecular level in animal models of acute kidney injury and chronic kidney disease; Reducing the inflammatory response, in the detection of renal biochemical function, can increase the UPCR ratio and improve blood biochemical indicators, showing a huge potential for the treatment of renal disease .
-
The financial reports of multinational pharmaceutical companies have been released one after another, and the revenue of many companies in China has exceeded 16 billion yuan
Time of Update: 2022-03-06
According to the 2021 annual report released by Merck, the company's revenue in 2021 will increase by 17% year-on-year to $48.
Roche According to Roche's recently released 2021 financial report, the company's sales in 2021 will increase by 8% year-on-year to 62.
-
A new batch of generic drug reference preparation catalogues are announced!
Time of Update: 2022-03-06
On January 7, 2022, the catalogue of generic drug reference preparations (the 50th batch) was released, and a total of 70 varieties were included.
It is understood that since 2016, China has released a total of 51 batches of chemical generic drug reference preparation catalogues.
-
In 2022, mergers and acquisitions of biopharmaceutical companies may be more active
Time of Update: 2022-03-06
Among them, in terms of merger and acquisition value, there are at least 4 transactions with a value of more than 10 billion US dollars, including Australian biotechnology companies CSL, Thermo Fisher, Merck and Siemens .
-
ASCO GU: PARP inhibitor PK game Lynparza may be better than Zejula in prostate cancer
Time of Update: 2022-03-06
PROpel in newly diagnosed metastatic castration resistance with or without homologous recombination repair (HRR) mutations In men with prostate cancer (mCRPC), Lynparza + Zytiga + steroids reduced the risk of disease progression or death by 34% compared to standard-of-care therapy Zytiga (abiraterone acetate) + steroids (HR=0.
-
The first subject enrolled in the Phase III clinical trial of Yuandong Bio-Udagliptin in the treatment of type 2 diabetes mellitus
Time of Update: 2022-03-06
Eudagliptin Tablets is a new class 1 chemical drug independently developed by the company and is the first oral DPP-4-week preparation for the treatment of type 2 diabetes in China .
-
The national procurement of proprietary Chinese medicines is approaching, and pharmaceutical machine companies usher in new opportunities
Time of Update: 2022-03-06
In recent years, the local government has also carried out a centralized procurement pilot for some varieties of Chinese patent medicines with large demand and high amount, and achieved certain results .
-
Breakthrough Research Progress of Small Molecule Anti-COVID-19 Drugs
Time of Update: 2022-03-05
Currently, drug development for SARS-CoV-2 mainly targets one or more events in the viral life cycle to prevent viral replication, such as blocking the binding of the spike protein to angiotensin-converting enzyme 2 (ACE2) and inhibiting the virus Membrane fusion with host cells or inhibition of 3CL protease (3C-likeprotease, 3CLpro) and papain (PLpro) or inhibition of RNA-dependent RNA polymerase (RdRp) and so on .
-
The seventh batch of national procurement enterprises began to declare a total of 208 product regulations
Time of Update: 2022-03-05
On February 17, Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on Carrying out the Information Reporting of the Seventh Batch of State-Organized Centralized Drug Procurement".
On February 17, Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on Carrying out the Information Reporting of the Seventh Batch of State-Organized Centralized Drug Procurement".
-
The biomacromolecule drug industry is in the ascendant, and equipment will receive more attention
Time of Update: 2022-03-05
At present, although the domestic CDMO industry is still dominated by small-molecule CDMO companies, the field of macromolecular drugs in China has risen rapidly since around 2016, and the development momentum has become stronger in the past two years.
